Aquestive Therapeutics (AQST) Short term Debt (2018 - 2026)

Aquestive Therapeutics' Short term Debt history runs 9 years deep, the most recent figure standing at $13.7 million for Q1 2026.

• In Q1 2026, Short term Debt rose 50496.3% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $13.7 million (up 50496.3% YoY), while the FY2025 annual figure was $10.0 million, up 38338.46% from the prior year.
• Short term Debt was $13.7 million for Q1 2026 at Aquestive Therapeutics, up from $10.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $18.7 million in Q4 2022 to a low of $22000.0 in Q4 2023.
• Historically, Short term Debt has averaged $7.2 million across 5 years, with a median of $6.3 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Short term Debt sank 99.88% in 2023, then jumped 50496.3% in 2026.
• A 5-year view of Short term Debt shows it stood at $18.7 million in 2022, then tumbled by 99.88% to $22000.0 in 2023, then increased by 18.18% to $26000.0 in 2024, then surged by 38338.46% to $10.0 million in 2025, then jumped by 36.69% to $13.7 million in 2026.
• The last three Short term Debt figures came in at $13.7 million (Q1 2026), $10.0 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.